5-(3-methylphenoxy)-2(1H)-pyrimidinone,
MLR-1023,
TOLIMIDONE,
41964-07-2,
MLR-1023,
CP-26154,
MLR 1023,
5-(m-tolyloxy)pyrimidin-2(1H)-one,
UNII-MU3JD8E9IS,
2(1H)-Pyrimidinone, 5-(3-methylphenoxy)-,
5-(3-methylphenoxy)-2(1h)-pyrimidinone,
MU3JD8E9IS,
5-(3-methylphenoxy)-1H-pyrimidin-2-one,
Tolimidone [USAN:INN],
Tolimidone (USAN),
AC1L20ZP,
CHEMBL8030,
MLS006012600,
SCHEMBL637505,
GTPL9433,
AOB1019,
DTXSID50194786,
QCR-285,
SYN5050,
BCP06813,
EX-A1338,
MFCD00866900,
NSC314335,
s8321,
ZINC17120697,
5-(m-Tolyloxy)-2(1H)-pyrimidinone,
AKOS000282153,
API0010573,
CS-7936,
NSC 314335,
NSC-314335,
SB17288,
NCGC00370768-04,
AJ-69962,
AS-16416,
CP 26154,
HY-59047,
SMR004704144,
CP-26,154,
B5648,
MLR-1023, >=98% (HPLC),
A12417,
D06182,
L-2205,
74078-86-7,
D0ZU4U,
O(c1cnc(O)nc1)c2cccc(C)c2,
C11H10N2O2,
CID39065,
5-(3-Methylphenoxy)-2(1H)-pyrimidinone, 95+%,
Oral kinase activator (theraTRACE, oral, type 2 diabetes), Melior,